1. Campo E. et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications // Blood. 2011. Vol. 117, N 19. P. 5019–5032.
2. Johansson P. et al. Percentage of smudge cells determined on routine blood smears is a novel prognostic factor in chronic lymphocytic leukemia // Leuk. Res. 2010. Vol. 34, N 7. P. 892–898.
3. Marti G.E. et al. Diagnostic criteria for monoclonal Bcell lymphocytosis // Br. J. Haematol. 2005. Vol. 130, N 3. P. 325–332.
4. Strati P., Shanafelt T.D. Monoclonal Bcell lymphocytosis and earlystage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification // Blood. 2015. Vol. 126, N 4. P. 454–462.
5. Rawstron A.C. et al. Monoclonal Bcell lymphocytosis and chronic lymphocytic leukemia // N. Engl. J. Med. 2008. Vol. 359, N 6. P. 575–583.
6. Moreau E.J. et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b) // Am. J. Clin. Pathol. 1997. Vol. 108, N 4. P. 378-382.
7. Ginaldi L. et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias // J. Clin. Pathol. 1998. Vol. 51, N 5. P. 364–369.
8. Matutes E. et al. The immunological profile of Bcell disorders and proposal of a scoring system for the diagnosis of CLL // Leukemia. 1994. Vol. 8, N 10. P. 1640–1645.
9. Morice W.G. et al. Predictive value of blood and bone marrow flow cytometry in Bcell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients // Mayo Clin. Proc. 2008. Vol. 83, N 7. P. 776–785.
10. Rawstron A.C. et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project // Cytometry B Clin. Cytom. 2018. Vol. 94, N 1. P. 121–128.
11. Orchard J.A. et al. ZAP70 expression and prognosis in chronic lymphocytic leukaemia // Lancet. 2004. Vol. 363, N 9403. P. 105–111.
12. Crespo M. et al. ZAP70 expression as a surrogate for immunoglobulinvariable-region mutations in chronic lymphocytic leukemia // N. Engl. J. Med. 2003. Vol. 348, N 18. P. 1764–1775.
13. Rassenti L.Z. et al. ZAP70 compared with immunoglobulin heavychain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia // N. Engl. J. Med. 2004. Vol. 351, N 9. P. 893–901.
14. Ibrahim S. et al. CD38 expression as an important prognostic factor in Bcell chronic lymphocytic leukemia // Blood. 2001. Vol. 98, N 1. P. 181–186.
15. Lin K. et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia // Blood. 2002. Vol. 100, N 4. P. 1404–1409.
16. Ghia P. et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression // Blood. 2003. Vol. 101, N 4. P. 1262–1269.
17. Boonstra J.G. et al. CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (BCLL): comparison of three approaches to analyze its expression // Cytometry B Clin. Cytom. 2006. Vol. 70, N 3. P. 136–141.
18. Kröber A. et al. Additional genetic highrisk features such as 11q deletion, 17p deletion, and V321 usage characterize discordance of ZAP70 and VH mutation status in chronic lymphocytic leukemia // J. Clin. Oncol. 2006. Vol. 24, N 6. P. 969–975.
19. Bulian P. et al. CD49d is the strongest flow cytometrybased predictor of overall survival in chronic lymphocytic leukemia // J. Clin. Oncol. 2014. Vol. 32, N 9. P. 897–904.
20. Dal Bo M. et al. Functional and clinical significance of the integrin alpha chain CD49d expression in chronic lymphocytic leukemia // Curr. Cancer Drug Targets. 2016. Vol. 16, N 8. P. 659–668.
21. Hallek M. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL // Blood. 2018. Vol. 131, N 25. P. 2745–2760.
22. National Comprehensive Cancer Network. Chronic lymphocytic leukemia (Version 2, 2019). 2019 April. URL: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/pro fessionals/physician_gls/pdf/cll.pdf
23. Eichhorst B. et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup // Ann. Oncol. 2021. Vol. 32, N 1. P. 23–33.
24. Абдурахманов Д.Т., Абузарова Г.Р., Агеева Т.А., Алексеев С.М., АльРади Л.С., Асланиди И.П. и др. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Москва : Буки Веди, 2018.
25. Jain P. et al. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a singlegroup, phase 2 trial // Lancet Haematol. 2017. Vol. 4, N 2. P. e67–e74.
26. Cramer P. et al. Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual // Leuk. Res. 2014. Vol. 38, N 3. P. 284–285.
27. Schroeder H.W. Jr, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire // Immunol. Today. 1994. Vol. 15, N 6. P. 288–294.
28. Fais F. et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors // J. Clin. Invest. 1998. Vol. 102, N 8. P. 1515–1525.
29. Hashimoto S. et al. Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells // J. Exp. Med. 1995. Vol. 181, N 4. P. 1507–1517.
30. Damle R.N. et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia // Blood. 1999. Vol. 94, N 6. P. 1840–1847.